Relevant bibliographies by topics / Anti-Saccharomyces cerevisiae antibody

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Conference papers

Academic literature on the topic 'Anti-Saccharomyces cerevisiae antibody'

Author: Grafiati
Published: 25 May 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anti-Saccharomyces cerevisiae antibody.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anti-Saccharomyces cerevisiae antibody"

1

Fedrigo, Aiessa, Thelma L. Skare, André Luiz Bortoluzzi, and Renato Nisihara. "ASCA (Anti-Saccharomyces cerevisiae Antibody) in Patients With Scleroderma." JCR: Journal of Clinical Rheumatology 25, no. 1 (2019): 24–27. http://dx.doi.org/10.1097/rhu.0000000000000759.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Oshitani, Nobuhide. "Anti-Saccharomyces Cerevisiae Antibody and 5-aminosalicylic Acid Treatment." American Journal of Gastroenterology 99, no. 5 (2004): 955. http://dx.doi.org/10.1111/j.1572-0241.2004.40044.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Teml, Alexander, and Walter Reinisch. "Anti-Saccharomyces Cerevisiae Antibody and 5-aminosalicylic Acid Treatment: Response." American Journal of Gastroenterology 99, no. 5 (2004): 956. http://dx.doi.org/10.1111/j.1572-0241.2004.40193.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Oshitani, N., F. Hato, Y. Jinno, et al. "IgG subclasses of anti Saccharomyces cerevisiae antibody in inflammatory bowel disease." European Journal of Clinical Investigation 31, no. 3 (2001): 221–25. http://dx.doi.org/10.1046/j.1365-2362.2001.00798.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Filik, Levent, and Ibrahim Biyikoglu. "Differentiation of Behcet’s disease from inflammatory bowel diseases: Anti-saccharomyces cerevisiae antibody and anti-neutrophilic cytoplasmic antibody." World Journal of Gastroenterology 14, no. 47 (2008): 7271. http://dx.doi.org/10.3748/wjg.14.7271.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tandio Saputro, Shania Safera, Khayu Wahyunita, Astutiati Nurhasanah, et al. "Expression of modified enhanced green fluorescent polyarginine protein in Saccharomyces cerevisiae INVSc1." F1000Research 12 (January 3, 2023): 1. http://dx.doi.org/10.12688/f1000research.123181.1.

Full text
Abstract:
Background: The enhanced green fluorescent protein (EGFP) gene is a reporter gene that can be used to optimize protein isolation procedures and the functional working of a transduction protein. EGFP, with the addition of eleven arginine residues, has been engineered to functionally improve the protein transduction process, which can later be used for cell reprogramming like induced pluripotent stem cells. The addition of six histidine amino acid residues at its C-terminal is intended for the protein isolation process using the His-tag antibody. Methods: The study aimed to investigate the optim
APA, Harvard, Vancouver, ISO, and other styles
7

Vermeire, Severine, Sofie Joossens, Marc Peeters, et al. "Comparative study of ASCA (Anti–Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease." Gastroenterology 120, no. 4 (2001): 827–33. http://dx.doi.org/10.1053/gast.2001.22546.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Makharia, Govind K., Vikas Sachdev, Rajiva Gupta, Suman Lal, and R. M. Pandey. "Anti-Saccharomyces cerevisiae Antibody Does Not Differentiate Between Crohn's Disease and Intestinal Tuberculosis." Digestive Diseases and Sciences 52, no. 1 (2006): 33–39. http://dx.doi.org/10.1007/s10620-006-9527-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Choi, Chang Hwan, Tae Il Kim, Byung Chang Kim та ін. "Anti-Saccharomyces cerevisiae Antibody in Intestinal Behçetʼs Disease Patients: Relation to Clinical Course". Diseases of the Colon & Rectum 49, № 12 (2006): 1849–59. http://dx.doi.org/10.1007/s10350-006-0706-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Belazi, Maria, Alexandra Fleva, Drakoulis Drakoulakos, and Despina Panayiotidou. "Comparison of salivary IgA and systemic IgA and IgG antibodies to Saccharomyces cerevisiae in HIV-infected subjects." International Journal of STD & AIDS 14, no. 7 (2003): 458–62. http://dx.doi.org/10.1258/095646203322025759.

Full text
Abstract:
Our objective was to investigate the concentrations of IgA and IgG antibodies to Saccharomyces cerevisiae in whole saliva and serum samples from HIV-infected patients and to compare them with the corresponding antibody values of healthy controls. A cross-sectional design was used. The test group consisted of 23 HIV-infected male individuals, aged 20-41 years old, free of any other systemic disease. Twenty healthy subjects aged 27-43 years old served as controls. Whole unstimulated saliva and blood were collected from all subjects. IgA concentrations in saliva and IgA and IgG concentrations in
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Anti-Saccharomyces cerevisiae antibody"

1

Cornu, Marjorie. "Mycobiome et maladies inflammatoires chroniques de l'intestin : Impact de la dysbiose sur l'inflammation intestinale et le processus fibrotique." Electronic Thesis or Diss., Université de Lille (2022-....), 2024. https://pepite-depot.univ-lille.fr/ToutIDP/EDBSL/2024/2024ULILS010.pdf.

Full text
Abstract:
Introduction. Alors que le mycobiote représente une part quantitative négligeable, en apparence, du microbiote intestinal, les preuves de son rôle dans les maladies inflammatoires chroniques de l’intestin, et notamment la maladie de Crohn (MC), sont croissantes. Ce travail avait pour objectif d’évaluer l’impact de Candida albicans et Saccharomyces cerevisiae sur l’inflammation et la fibrose intestinale (FI), mais également sur la production des anticorps anti-S. cerevisiae (ASCA), reconnaissant des séquences oligomannosidiques de faible degré de polymérisation ayant un résidu α,1-3 mannose ter
APA, Harvard, Vancouver, ISO, and other styles
2

Brito, Ana Sofia da Costa e. "Saccharomyces cerevisiae strains expressing human KRAS as tools for targeting therapeutic anti-EGFR-RAS pathway antibody - drugs." Master's thesis, 2015. http://hdl.handle.net/1822/35686.

Full text
Abstract:
Dissertação de mestrado em Genética Molecular<br>Fundamental cellular processes appear to be highly conserved between Saccharomyces cerevisiae and other more complex Eukaryotic species, including humans. “Humanized yeast systems” emerged as a tool to study molecular aspects of human pathologies. The present work aimed at contributing to build and validate a large high throughput platform of yeast strains displaying phenotypes that can enable further testing galectin-related drugs and peptides. This platform was designed to consist of two types of strains, the ones expressing human galecti
APA, Harvard, Vancouver, ISO, and other styles
3

Puga, Sónia Andreia Silva. "Identification of the Saccharomyces cerevisiae target of Cetuximab-Erbitux, the anti-EGFR antibody used in the treatment of colorectal cancer." Master's thesis, 2013. http://hdl.handle.net/1822/23721.

Full text
Abstract:
Dissertação de mestrado em Genética Molecular<br>Colorectal cancer (CRC) is one of the most common malignancies affecting mankind. CRC cells over-express epidermal growth factor receptor (EGFR), which usually correlates with disease poor prognosis and reduced response to therapy. Hence, several therapeutic agents against EGFR were developed, viz. the monoclonal antibody cetuximab/Erbitux®. Such drug competes with EGFR ligands for binding to L2/III domain, which results in EGFR internalization and subsequent degradation, leading to inhibition of cell growth and angiogenesis, and induction
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anti-Saccharomyces cerevisiae antibody"

1

Song, Yang, Jingtong Wu, Zhangran Chen, and Hongzhi Xu. "IDDF2023-ABS-0245 Saccharomyces cerevisiae and serum anti-saccharomyces cerevisiae antibody is associated with the progression of hepatitis B virus infection." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 10–11 June 2023. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2023. http://dx.doi.org/10.1136/gutjnl-2023-iddf.38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Puteri, S. A., S. Pambudi, A. F. Rahmani, T. Subiantistha, and R. Lestari. "Cloning of recombinant fab from monoclonal antibody anti-dengue NS1 induced by Saccharomyces cerevisiae in Escherichia coli TOP10." In PROCEEDINGS OF THE 4TH INTERNATIONAL SYMPOSIUM ON CURRENT PROGRESS IN MATHEMATICS AND SCIENCES (ISCPMS2018). AIP Publishing, 2019. http://dx.doi.org/10.1063/1.5132530.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fedrigo, A., TAFG dos Santos, A. Bortoluzzi, T. Skare, and R. Nisihara. "AB0186 ASCA (anti-saccharomyces cerevisae antibody) in scleroderma." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.4305.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Anti-Saccharomyces cerevisiae antibody' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography